Servier, a global pharmaceutical company, has successfully completed its acquisition of Agios Pharmaceuticals’ commercial, clinical and research-stage oncology portfolio for up to $2 billion plus royalties. The acquisition strengthens Servier’s commercial presence in the U.S. malignant hematology market and provides the potential for long-term growth into the solid tumor space.   “We are pleased to welcome an exceptionally talented team that will allow us to strengthen our stra...